After its parent company AGC Inc. acquired 100% of the shares of MolMed S.p.A. on September 30, 2020, AGC Biologics said that MolMed’s entity name has been changed to AGC Biologics S.p.A.
 
This Center of Excellence for AGC Biologics’ cell and gene therapy contract development and manufacturing organization (CDMO) services is in Milan, Italy. The Milan site was the first GMP facility approved in Europe for ex-vivo gene therapy manufacturing and has commercial manufacturing experience, with two cell and gene therapy products. AGC Biologics says it is now one of the few CDMOs in the world offering both plasmid production and end-to-end cell and gene therapy services.
 
Because MolMed was a listed company, the share acquisition was completed via a tender offer for the shares of the company, all completed on September 30, at which time AGC Inc. acquired 100% of the shares and MolMed S.p.A. was delisted from the Milan Stock Exchange.
 
“AGC Biologics is very pleased to now offer end-to-end cell and gene therapy CDMO services to our current and future customers,” says Patricio Massera, chief executive officer, AGC Biologics. “Our new team in Milan brings deep expertise and experience gained over 25 years developing and producing cell and gene therapies for the treatment of cancer and rare diseases.”